Events - Spark Newswire

4 minute read

AbbVie Announces Late-Breaking Results From Phase 2 Exploratory NOVA Trial Of Novel Investigational Neurotoxin AGN-151607 For The Prevention Of Postoperative Atrial Fibrillation In Cardiac Surgery Patients, Primary Endpoint Was Not Met

Today, 7:47 PM

Primary endpoint was not met for the modified intent-to-treat (mITT) population; however, clinical benefit observed in coronary artery bypass graft (CABG) patients

ABBV

5 minute read

Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial Of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session At AHA Scientific Sessions 2022; Says Trial Met Primary Endpoint

By Benzinga Newsdesk

Today, 7:47 PM

Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001) Median time to

MIST

2 minute read

Is CZ Spreading Rumors? Bankman-Fried Thinks So: Binance, FTX Drama Continues

By Murtuza Merchant

Today, 7:47 PM

FTX CEO Sam Bankman-Fried clapped back at rival Binance CEO Changpeng Zhao after the latter apparently threw shade at the billionaire via Twitter.

$FTT

3 minute read

Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies And Next Generation Commercial-Scale Manufacturing Platform At SITC 37th Annual Meeting

By Benzinga Newsdesk

Today, 7:47 PM

Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors

NKTX

3 minute read

NextCure Presents Initial Data From Clinical Trial Of NC762 And A Trial In Progress Poster For NC410 Combo At The 2022 Society For Immunotherapy Of Cancer Annual Meeting

By Benzinga Newsdesk

Today, 7:47 PM

NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today

NXTC

4 minute read

Fate Therapeutics Announces Exercise By ONO Pharmaceutical Of Option To HER2-Targeted CAR T-Cell Product Candidate For Solid Tumors

By Benzinga Newsdesk

Today, 7:47 PM

Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Potent and Specific CAR Activity Across Multiple Preclinical Solid Tumor Models Fate and ONO to Jointly Develop and

FATE

5 minute read

BrainStorm Cell Therapeutics Presents New Analyses From NurOwn’s Phase 3 ALS Trial At The 21st Annual NEALS Meeting

By Benzinga Newsdesk

Today, 7:47 PM

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of a poster with new analyses from NurOwn's

BCLI

4 minute read

Events
News

Vir Biotechnology Presenting New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD Liver Meeting

By Charles Gross

Today, 7:47 PM

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure.

VIR

2 minute read

Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data At The American Society Of Nephrology Kidney Week 2022 Meeting

By Benzinga Newsdesk

Today, 7:47 PM

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today presented a poster at the American

ALPN

2 minute read

Hey, Mark Cuban! You’re Invited To Benzinga’s December 2022 NYC Crypto And Fintech Events. See You There?

By Justin Roberti

Today, 7:47 PM

Benzinga cordially invites Mark Cuban to attend its next event on Dec. 7-8, 2022, at NYC’s Pier Sixty. No RSVP is required. Just show up, and we’ll cover your stay, too!

$AAVE